Wells Fargo Raises its Price Target on MannKind (MNKD) to $10

MannKind Corporation (NASDAQ:MNKD) is one of the 10 Best Penny Stocks to Buy Before They Explode.

On May 7, 2026, Wells Fargo raised the firm’s price target on MannKind Corporation (NASDAQ:MNKD) to $10 from $8 while maintaining an Overweight rating following disclosure of the company’s involvement with ralinepag DPI and ahead of upcoming PDUFA decisions tied to Afrezza and Furoscix. The firm said it now sees multiple potential avenues for revenue growth.

Similarly, H.C. Wainwright raised its price target on MannKind Corporation (NASDAQ:MNKD) to $10 from $8 while maintaining a Buy rating. The firm said Q1 results came in below expectations, though that does not alter its broader investment thesis, which is increasingly centered on the durability and upside potential of MannKind’s royalty and collaboration revenue streams. H.C. Wainwright also cited potential pipeline upside in support of the target increase.

A day earlier, MannKind Corporation (NASDAQ:MNKD) reported Q1 EPS of (2c), versus the consensus estimate of 1c. Revenue totaled $90.17M, versus the consensus estimate of $105.31M. CEO Michael Castagna said the company continues making progress on its corporate transformation strategy focused on expanding and diversifying both its commercial portfolio and development pipeline. Castagna described 2026 as the most catalyst-rich year in MannKind’s history. Castagna added that potential approval of the Furoscix ReadyFlow Autoinjector could help accelerate the brand’s growth trajectory, while a potential pediatric expansion for Afrezza could address unmet needs in a new patient population. Castagna also pointed to continued momentum from Tyvaso DPI, including expansion into IPF, along with the company’s expanded collaboration with United Therapeutics involving ralinepag DPI.

MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company focused on developing therapies and technologies for chronic disease care.

While we acknowledge the risk and potential of MNKD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MNKD and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.